← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Etubics Corporation
Seattle, WA
$16,079,498
Total funding
14
Grants
Funding over time
peak $3M · FY2006–18$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$16,079,498 · 14
By mechanism
R44$6,957,930 · 3
R01$4,460,696 · 1
N44$2,977,851 · 2
R43$1,224,001 · 5
N43$349,964 · 2
R03$109,056 · 1
Investigators at Etubics Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
TAS::75 0849 - TOPIC 255 PHASE II, CGMP MANUFACTURE OF A NOVEL CEA EXPRESSING A$1,499,001
N44 · FY2011 · CA
Development of a Novel CEA Expressing Ad5 [E1-, E2b-] Vector for Treatment$1,488,231
R44 · FY2009 · CA
IGF::OT::IGF SBIR TOPIC 255 cGMP Manufacture of$1,478,850
N44 · FY2013 · CA
Development of a Universal Influenza Vaccine$1,398,670
R01 · FY2014 · AI
Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee$1,149,641
R44 · FY2010 · AI
Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee$1,133,414
R44 · FY2011 · AI
Development of a Universal Influenza Vaccine$1,121,460
R01 · FY2015 · AI
Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee$1,070,762
R44 · FY2009 · AI
Development of a Novel CEA Expressing Ad5 [E1-, E2b-] Vector for Treatment$982,054
R44 · FY2010 · CA
Development of a Universal Influenza Vaccine$734,209
R01 · FY2018 · AI
Therapeutic Vaccine for HIV/HPV-associated Oropharyngeal and Tonsillar Malignanci$619,720
R44 · FY2013 · DE
Development of a Universal Influenza Vaccine$612,096
R01 · FY2017 · AI
Development of a Universal Influenza Vaccine$594,261
R01 · FY2016 · AI
Therapeutic Vaccine for HIV/HPV-associated Oropharyngeal and Tonsillar Malignanci$414,421
R44 · FY2014 · DE
Improved HIV-Adenoviral Vector Vaccine for Re-immunization$312,875
R43 · FY2007 · AI
Improved HIV-Adenoviral Vector Vaccine for Re-immunization$308,505
R43 · FY2006 · AI
Development of an Ad5-CEA/Brachyury Vector Approach for Cancer Treatment$202,654
R43 · FY2014 · CA
TAS::75 0849::TAS TOPIC 255 CGMP MANUFACTURE OF A NOVEL HER2/NEU EXPRESSING ADEN$199,988
N43 · FY2011 · CA
Therapeutic Vaccine for HIV/HPV-associated Oropharyngeal and Tonsillar Malignanci$163,405
R43 · FY2011 · DE
SBIR TOPIC 255 DEVELOPMENT OF ANTICANCER AGENTS$149,976
N43 · FY2009 · CA